Davoodi-Semiromi, Abdoreza <br/><br/>
Tyrphostin AG490 agent modestly but significantly prevents onset of type 1 in NOD mouse; implication of immunologic and metabolic effects of a Jak-Stat pathway inhibitor.  [electronic resource] 

 -  Journal of clinical immunology  Oct 2012 
 - 1038-47 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, American Recovery and Reinvestment Act; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-2592 
<br/><br/><label>Standard No.: </label>10.1007/s10875-012-9707-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Blood Glucose--analysis<br/>Bone Marrow Cells--cytology<br/>CD4-Positive T-Lymphocytes--immunology<br/>Cells, Cultured<br/>Dendritic Cells<br/>Diabetes Mellitus, Type 1--blood<br/>Female<br/>Forkhead Transcription Factors--immunology<br/>Interleukin-2 Receptor alpha Subunit--immunology<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Inbred NOD<br/>PPAR gamma--immunology<br/>Protein Kinase Inhibitors--therapeutic use<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>STAT Transcription Factors--immunology<br/>Tyrphostins--therapeutic use